Department of Psychiatry, Brigham and Women's Hospital, Boston, MA (JS); Harvard Medical School, Boston, MA (JS, RDW); Division of Drug and Alcohol Abuse, McLean Hospital, Belmont, MA (RDW).
J Addict Med. 2021 Apr 1;15(2):91-92. doi: 10.1097/ADM.0000000000000711.
With the growing public interest in the potential therapeutic benefits of cannabis and cannabinoids in the treatment of opioid use disorder (OUD), some states have now either added or proposed to add OUD as an indication for their state's medical marijuana program. However, these initiatives are based on weak evidence which at present do not support the listing of cannabis or cannabinoids as a treatment for OUD. Nevertheless, studying the potential therapeutic applications of carefully chosen components of cannabis or cannabinoids to treat specific aspects of OUD is not without scientific merit. Given the high rates of treatment discontinuation among those taking medications for OUD, interventions that further improve clinical outcomes are especially needed. The potential therapeutic applications of cannabis and cannabinoids in the treatment of OUD are worthy of further study, but it should be conducted with the same rigor that we expect of all pharmaceutical products. Until we have more research to show their efficacy, policy makers and clinicians should refrain from portraying cannabis and cannabinoids as evidence-based treatments for OUD.
随着公众对大麻和大麻素在治疗阿片类药物使用障碍(OUD)方面的潜在治疗益处的兴趣日益浓厚,现在一些州已经将 OUD 添加到或提议添加到其州的医用大麻计划中。然而,这些举措的依据是薄弱的证据,目前并不支持将大麻或大麻素列为 OUD 的治疗方法。尽管如此,研究大麻或大麻素中精心挑选的成分治疗 OUD 特定方面的潜在治疗应用并非没有科学意义。鉴于接受 OUD 药物治疗的患者中有很高的治疗中断率,特别需要进一步改善临床结果的干预措施。大麻和大麻素在治疗 OUD 方面的潜在治疗应用值得进一步研究,但应该像我们对所有药物产品一样严格进行。在我们有更多研究表明它们的疗效之前,政策制定者和临床医生不应将大麻和大麻素描绘为治疗 OUD 的循证治疗方法。